CN103299192B - 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记 - Google Patents

与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记 Download PDF

Info

Publication number
CN103299192B
CN103299192B CN201180053583.9A CN201180053583A CN103299192B CN 103299192 B CN103299192 B CN 103299192B CN 201180053583 A CN201180053583 A CN 201180053583A CN 103299192 B CN103299192 B CN 103299192B
Authority
CN
China
Prior art keywords
diabetes
subject
biomarker
protein
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180053583.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103299192A (zh
Inventor
托马斯·斯托尔
斯科特·伯林根斯
凯耶·温菲尔德
塔米·凯西
温迪·戴维斯
柯尔斯顿·彼得斯
蒂莫西·戴维斯
理查德·利普斯科姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteomics International Pty Ltd
Original Assignee
University of Western Australia
Proteomics International Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904249A external-priority patent/AU2010904249A0/en
Application filed by University of Western Australia, Proteomics International Pty Ltd filed Critical University of Western Australia
Priority to CN201610302678.4A priority Critical patent/CN105974123A/zh
Publication of CN103299192A publication Critical patent/CN103299192A/zh
Application granted granted Critical
Publication of CN103299192B publication Critical patent/CN103299192B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90212—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
CN201180053583.9A 2010-09-21 2011-09-20 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记 Active CN103299192B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610302678.4A CN105974123A (zh) 2010-09-21 2011-09-20 与糖尿病前期、糖尿病及糖尿病相关病症相关的生物标记

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010904249A AU2010904249A0 (en) 2010-09-21 Biomarkers associated with pre-diabetes,diabetes and diabetes related conditions
AU2010904249 2010-09-21
PCT/AU2011/001212 WO2012037603A1 (en) 2010-09-21 2011-09-20 Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610302678.4A Division CN105974123A (zh) 2010-09-21 2011-09-20 与糖尿病前期、糖尿病及糖尿病相关病症相关的生物标记

Publications (2)

Publication Number Publication Date
CN103299192A CN103299192A (zh) 2013-09-11
CN103299192B true CN103299192B (zh) 2016-05-11

Family

ID=45873304

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180053583.9A Active CN103299192B (zh) 2010-09-21 2011-09-20 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
CN201610302678.4A Pending CN105974123A (zh) 2010-09-21 2011-09-20 与糖尿病前期、糖尿病及糖尿病相关病症相关的生物标记

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610302678.4A Pending CN105974123A (zh) 2010-09-21 2011-09-20 与糖尿病前期、糖尿病及糖尿病相关病症相关的生物标记

Country Status (11)

Country Link
US (5) US20130177544A1 (enExample)
EP (3) EP3151012B1 (enExample)
JP (2) JP6271250B2 (enExample)
CN (2) CN103299192B (enExample)
AU (2) AU2011305050B2 (enExample)
BR (1) BR112013006764B1 (enExample)
CA (1) CA2811654C (enExample)
ES (2) ES2928585T3 (enExample)
RU (1) RU2596486C2 (enExample)
SG (1) SG188527A1 (enExample)
WO (1) WO2012037603A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151012B1 (en) * 2010-09-21 2018-03-21 Proteomics International Pty Ltd Biomarkers associated with diabetic nephropathy
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
WO2014034168A1 (ja) * 2012-08-30 2014-03-06 Hashida Seiichi 早期腎障害の評価マーカーとその測定方法
US11699527B2 (en) * 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
CN103473569A (zh) * 2013-09-22 2013-12-25 江苏美伦影像系统有限公司 基于svm的医学影像分类方法
JP5925391B2 (ja) * 2013-10-16 2016-05-25 日本水産株式会社 ペプチド又はその酸付加塩、飲食品、及び糖尿病予防等の組成物
US10267806B2 (en) 2014-04-04 2019-04-23 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
WO2018088521A1 (ja) 2016-11-11 2018-05-17 大塚製薬株式会社 肝の糖取込み能評価方法
PL3358355T3 (pl) * 2017-02-04 2024-04-08 Warszawski Uniwersytet Medyczny Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób
CN106645757B (zh) * 2017-03-13 2019-01-15 新疆医科大学 一种诊断早发糖尿病mody的血清蛋白标志物组及其应用
CN107144620A (zh) * 2017-03-31 2017-09-08 兰州百源基因技术有限公司 糖尿病肾病检测标志物
CN110914691B (zh) 2017-03-31 2024-07-26 奎斯特诊断投资有限公司 用于定量胰岛素和c-肽的方法
CN108732253A (zh) * 2017-04-14 2018-11-02 杭州量康科技有限公司 用于血清蛋白质定量测定的肽段组合物及测定方法
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
CA3103150A1 (en) * 2018-06-21 2019-12-20 China Medical University Protein biomarkers for nephropathy and applications thereof
JP7419340B2 (ja) * 2018-08-08 2024-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質バイオマーカーを定量するためのｌｃ－ｍｓ／ｍｓの使用
CN110286234B (zh) * 2019-07-02 2023-03-24 安肽和(杭州)医疗科技有限公司 尿液中妊娠糖尿病的蛋白质标志物及其在早期诊断中的用途
JP2023509677A (ja) * 2020-01-10 2023-03-09 ソマロジック オペレーティング カンパニー インコーポレイテッド 耐糖能異常障害を決定する方法
CN111876479A (zh) * 2020-06-29 2020-11-03 中国人民解放军总医院 基于尿沉渣特定微小rna无创鉴别诊断糖尿病肾病/非糖尿病性肾病方面的应用
CN117310148A (zh) * 2023-09-11 2023-12-29 杭州珞米医疗科技有限公司 一种蛋白标志物作为生物标志物的用途
CN118534127A (zh) * 2024-04-12 2024-08-23 郑州大学 补体h因子相关蛋白作为糖尿病肾病诊断的生物标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028636A1 (en) * 2005-09-09 2007-03-15 Medizinische Universität Innsbruck Method for predicting the progression of chronic kidney disease by measuring apolipoprotein a-iv

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100640201B1 (ko) * 2004-12-07 2006-10-30 (주) 대홍기업 히트파이프가 설치된 도어 조립체 및 이 도어 조립체를채택한 김치저장고
CN101166981A (zh) * 2005-04-11 2008-04-23 阿斯利康(瑞典)有限公司 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒
WO2006122043A2 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Diagnostic marker for diabetic vascular complications
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US20070111245A1 (en) * 2005-11-09 2007-05-17 Ravi Thadhani Predicting diabetic nephropathy
CN101361001A (zh) * 2006-01-20 2009-02-04 马赛奎斯诊断和治疗有限公司 诊断肾病的方法和标志物
EP2005172A4 (en) * 2006-03-23 2009-05-06 Emelita De Guzman Breyer APOLIPOPROTEIN-FINGERPRINT PROCESS
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
KR100792630B1 (ko) * 2006-07-05 2008-01-09 고려대학교 산학협력단 당뇨병성 신증 진단용 바이오 마커
EP2469283B1 (en) * 2006-09-08 2014-01-15 The Chancellor, Masters and Scholars of the University of Oxford Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
WO2009126271A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
US8673644B2 (en) * 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
EP2307544A4 (en) * 2008-06-13 2012-09-05 Prognomix Inc GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES
EP2307050A4 (en) * 2008-07-04 2012-07-25 Ono Pharmaceutical Co USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
WO2010005982A2 (en) * 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
US8735443B2 (en) * 2008-10-21 2014-05-27 Kuwait University Method of treating diabetes-related vascular complications
CA2750818A1 (en) * 2009-01-27 2010-08-05 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
DK2623517T3 (en) * 2009-01-28 2015-11-23 Ind Tech Res Inst Urine and serum biomarkers associated with diabetic nephropathy
EP2510361A4 (en) * 2009-12-11 2013-07-17 Purdue Research Foundation DETECTION OF OXIDIZED POLYPEPTIDES
JPWO2011145725A1 (ja) * 2010-05-20 2013-07-22 宮崎　徹 Ａｉｍ関連疾患の診断方法及び診断用キット
EP3151012B1 (en) * 2010-09-21 2018-03-21 Proteomics International Pty Ltd Biomarkers associated with diabetic nephropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028636A1 (en) * 2005-09-09 2007-03-15 Medizinische Universität Innsbruck Method for predicting the progression of chronic kidney disease by measuring apolipoprotein a-iv

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Association and interaction analyses of genetic variants in ADIPOQ, ENPP1,GHSR,PPARγ and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes;LawrenceS hih-Hsin Wu;《Nephro lDial Transplant》;20090608;第24卷;第3360-3366页 *
Association of Adiponect in Gene Polymorphisms With Type2DiabetesinanAfricanAmericanPopulation Enriched for Nephropathy;Meredith A.Bostrom;《DIABETES》;20090228;第58卷;第499-504页 *
Gene and protein markers of diabetic nephropathy;Claude Granier;《Nephrol Dial Transplant》;20071208;第23卷;第792-799页 *
Increment and impairment of adiponectin inrenal failure;Noriyuki Komura;《Cardiovascular Research》;20091224;第86卷;第471-477页 *
Novel roles of the IGF–IGFBP axis in etiopathophysiology of diabetic nephropathy;Tetyana L;《Diabetes Research and Clinical Practice》;20061002;第76卷;第182页右栏第3段，第183页左栏第2段，表1 *
Proteomic Identification of Urinary Biomarkers of Diabetic Nephropathy;PATURI V.RAO;《DIABETES CARE》;20071231;第30卷(第3期);第629-637页 *
Serum Adiponectin and Progression of Diabetic Nephropathy in Patients With type 1 Diabetes;MARKKU SARAHEIMO;《DIABETES CARE》;20080630;第3卷;第1165-1169页 *
Tetyana L.Novel roles of the IGF–IGFBP axis in etiopathophysiology of diabetic nephropathy.《Diabetes Research and Clinical Practice》.2006,第76卷第177-186页. *
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes;Veikko Salomaa;《PLoS ONE》;20100409;第5卷(第4期);第1-8页 *
中老年糖尿病肾病血清载脂蛋白水平分析;龙兆丰;《湖南医科大学学报》;19951231;第20卷(第5期);第460-462页 *

Also Published As

Publication number Publication date
US20150355198A1 (en) 2015-12-10
JP2013541706A (ja) 2013-11-14
US20130177544A1 (en) 2013-07-11
EP3343226B1 (en) 2022-07-27
US20170299613A1 (en) 2017-10-19
BR112013006764A2 (pt) 2016-06-28
HK1256827A1 (en) 2019-10-04
EP2619592A1 (en) 2013-07-31
ES2928585T3 (es) 2022-11-21
AU2015202230A1 (en) 2015-05-21
EP3151012A1 (en) 2017-04-05
AU2011305050B2 (en) 2015-05-21
EP3151012B1 (en) 2018-03-21
AU2015202230B2 (en) 2017-08-03
US10191067B2 (en) 2019-01-29
SG188527A1 (en) 2013-04-30
US9146243B2 (en) 2015-09-29
US20140249049A1 (en) 2014-09-04
US9733259B2 (en) 2017-08-15
AU2011305050A1 (en) 2013-03-28
RU2596486C2 (ru) 2016-09-10
CN103299192A (zh) 2013-09-11
ES2665910T3 (es) 2018-04-30
BR112013006764B1 (pt) 2020-11-03
RU2013113927A (ru) 2014-10-27
CA2811654C (en) 2020-06-30
EP2619592A4 (en) 2014-05-07
CN105974123A (zh) 2016-09-28
JP6271250B2 (ja) 2018-01-31
US20190107546A1 (en) 2019-04-11
EP3343226A1 (en) 2018-07-04
CA2811654A1 (en) 2012-03-29
WO2012037603A1 (en) 2012-03-29
JP2017223682A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
CN103299192B (zh) 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
Colhoun et al. Biomarkers of diabetic kidney disease
JP2013079981A (ja) 糖尿病に関連するバイオマーカーおよびその使用方法
JP2010502946A (ja) ２型糖尿病を診断および処置するための組成物および方法
WO2010011860A1 (en) Methods for detecting pre-diabetes and diabetes
WO2015111008A2 (en) Biomarkers predictive of muscle atrophy, method and use
CN103403548A (zh) 用于预测糖尿病的工具和方法
Xiao et al. The Clinical Characteristics and Potential Molecular Mechanism of LMNA Mutation‐Related Lipodystrophy
NO345378B1 (no) Deteksjon av løselige adisponektinreseptorpeptider og anvendelse i diagnostikk og terapi
HK1256827B (en) Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions
WO2015160786A1 (en) Method of diagnosing, prognosing, and treating lupus nephritis
Kim et al. Proteomics and its Application for Elucidating Insulin Deregulation in Diabetes
CN112083167A (zh) S100a4作为评估甲氨蝶呤干预银屑病的生物标记物及其用途
Swaminathan Kidney manifestations of diabetes mellitus-A Review

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180913

Address after: Western Australia, Australia

Patentee after: Proteomics International Pty Ltd

Address before: Western Australia, Australia

Co-patentee before: Univ Western Australia

Patentee before: Proteomics International Pty Ltd

TR01 Transfer of patent right